Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 17/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 17/20 | 0.50 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24317452 | 0.92 | CRBN (0.52) | DDB1CRBNBCL2L11BCL2MCL1 | |
| SCHEMBL29532505 | 0.92 | CRBN (0.52) | DDB1CRBNBCL2L11BCL2MCL1 | |
| SCHEMBL24317610 | 0.87 | CRBN (0.44) | DDB1CRBNBCL2L11BCL2MCL1 | |
| SCHEMBL24317575 | 0.85 | DDB1 (0.47) | DDB1CRBNBCL2L11BCL2MCL1 | |
| SCHEMBL27012683 | 0.85 | DDB1 (0.47) | DDB1CRBNBCL2L11BCL2MCL1 | |
| SCHEMBL24317479 | 0.85 | CRBN (0.50) | DDB1CRBNBCL2L11BCL2MCL1 | |
| SCHEMBL24317476 | 0.84 | CRBN (0.49) | DDB1CRBNBCL2L11BCL2MCL1 | |
| SCHEMBL27013009 | 0.83 | CRBN (0.41) | DDB1CRBNBCL2L11BCL2MCL1 | |
| SCHEMBL27012686 | 0.83 | CRBN (0.47) | DDB1CRBNBCL2L11BCL2MCL1 | |
| SCHEMBL24317477 | 0.82 | CRBN (0.56) | DDB1CRBNBCL2L11BCL2MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | DDB1 1733/4885CRBN 281/4885BCL2L11 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.